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Abstract
Objectives—Features of eosinophilic esophagitis (EoE) and gastroesophageal reflux disease
(GERD) overlap. We aimed to determine whether staining for tissue biomarkers would
differentiate EoE from GERD, suggesting utility for diagnosis of EoE.
Methods—In this case-control study, EoE patients defined by consensus guidelines were
compared to GERD patients with eosinophils on esophageal biopsy. Immunohistochemistry was
performed for major basic protein (MBP), eotaxin-3, leukotriene A4 hydrolase (LTA4H), and
leukotriene C4 synthase (LTC4S). After masking, the maximum staining density (cells/mm2) was
quantified for each marker and compared between groups. Receiver operator characteristic curves
were constructed, and the area under the curve (AUC) calculated to assess the diagnostic utility of
each of the biomarkers alone and in combination with eosinophil counts.
Results—There were 51 EoE cases (mean age 24; mean 143 eos/hpf) and 54 GERD controls
(mean age 34; mean 20 eos/hpf). The MBP density was higher in EoE than in GERD (1479 vs 59
cells/mm2; p<0.001), as was the eotaxin-3 density (2219 vs 479; p<0.001). There were no
differences for LTA4H and LTC4S. MBP density and eosinophil count correlated (R=0.81;
p<0.001); correlation with eotaxin-3 was weaker (R=0.25; p=0.01). The AUC for diagnosis of
EoE was 0.96 for MBP, 0.87 for eotaxin-3, 0.58 for LTA4H, 0.66 for LTC4S, and 0.99 for the
combination of MBP, eotaxin-3, and eosinophil count.
Conclusions—Patients with EoE had substantially higher levels of MBP and eotaxin-3 staining
than GERD patients. These markers may have utility as a diagnostic assay for EoE.
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Introduction
Eosinophilic esophagitis is a chronic immune-mediated disease characterized by symptoms
of esophageal dysfunction and a marked esophageal epithelial eosinophilic infiltrate, in the
absence of other potential causes of esophageal eosinophilia (1, 2). The clinical and
histologic features of EoE are not specific (1), and may overlap substantially with features of
gastroesophageal reflux disease (GERD) (1, 3, 4). Symptoms such as dysphagia and
heartburn are common in both conditions (1, 2, 5–9), and esophageal eosinophilia,
presumably the pathologic hallmark of EoE, is commonly seen on esophageal biopsies in
GERD as well (10–12). Therefore, it is often a major clinical challenge to differentiate EoE
and GERD.
Use of tissue biomarkers of eosinophil activation or inflammation may represent a more
efficient and pathophysiologically-based means for diagnosis of EoE and distinguishing it
from GERD (13, 14). The pathogenesis of EoE is felt to involve a Th2 response to allergen
exposure in which esophageal epithelial cells are stimulated to produce eotaxin-3, which in
turn leads to eosinophil activation and release of intracellular granules, including major
basic protein (MBP) (15–17). Other allergic pro-inflammatory mediators, including enzymes
in the arachidonic acid pathway such as leukotriene A4 hydrolase (LTA4H) and leukotriene
C4 synthase (LTC4S) that metabolize leukotriene precursors, may also be involved (18, 19).
While MBP and other eosinophil granule proteins have been shown to be more commonly
found in EoE (20–26), transcription of eotaxin-3 is highly upregulated in EoE (27–31), and
there is differential gene expression of LTA4H and LTCS4 (27), the diagnostic utility of
these factors has not been established in EoE.
The aims of this study were to determine whether staining for MBP, eotaxin-3, LTA4H, and
LTC4S in the esophageal epithelium differentiates EoE from GERD, and to assess the utility
of these assays for diagnosis of EoE. We hypothesized that patients with EoE would have a
greater number of cells staining for all of the selected tissue biomarkers, and that increasing
numbers of positively staining cells would correctly predict EoE case status.
Methods
Study design and patients
We conducted a case-control study of subjects in the University of North Carolina (UNC)
EoE Clinicopathologic database from 2000–2007. Details of the development of this
database and selected patient characteristics have previously been described (7, 14, 32).
Cases were patients of any age who had a new diagnosis of EoE as defined by the 2007
consensus guidelines (2). Because the majority of the cases were evaluated prior to the
publication of the guidelines, only those patients explicitly meeting all of the diagnostic
criteria when applied retrospectively were included in this study. Specifically, cases were
required to have at least one typical symptom of esophageal dysfunction (for example
dysphagia, food impaction, heartburn, or feeding intolerance); at least 15 eosinophils per
high-power field (eos/hpf) on esophageal biopsy; and had other causes of esophageal
eosinophilia, including reflux disease, excluded. GERD was excluded by documenting
persistent esophageal eosinophilia and symptoms despite high-dose acid suppression at the
time of biopsy (n = 32), by documenting persistent esophageal eosinophilia despite prior
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symptoms refractory to high-dose acid-suppression (n = 15), or with negative pH monitoring
(n = 4). Of note, these cases have previously been extensively characterized with
confirmation of the diagnosis of EoE (9, 14).
Controls were GERD patients of any age who underwent esophagogastroduodenoscopy
(EGD) and biopsy during the same time frame as the cases. GERD patients were defined by
having at least one typical symptom, including heartburn, regurgitation, pain, or, in children,
failure to thrive, which responded to anti-secretory therapy with either a proton pump
inhibitor (PPI) or a H2 receptor blocker. In addition, inflammation, including at least 1 eos/
hpf, was required on biopsy, and other competing causes of the presentation were excluded
by the clinical evaluation. We required some degree of eosinophilia in our GERD control
population to generate a clinically ambiguous group in whom EoE might be misdiagnosed,
and where the diagnostic challenge to the clinician was present. This group was felt to have
the most potential to benefit from an assay differentiating GERD from EoE.
Clinical data were extracted from the electronic medical record and endoscopy reports.
Factors of interest included: demographics (age at diagnosis, gender, race); symptoms; co-
existing atopic disease (allergic rhinitis or sinusitis, asthma, or documented food allergy
demonstrated by either symptomatic evidence of allergy with reintroduction of a food or by
testing directed by an Allergist; and endoscopic findings (rings, linear furrows, white
plaques or exudates, erosive esophagitis, and hiatal hernia).
Histology and immunohistochemistry
For histologic assessment, archived pathology slides were re-reviewed by the study
pathologists to determine eosinophil counts using a previously validated protocol (33). To
summarize, slides were masked as to case and control status and the maximum eosinophil
density (eosinophils/mm2 [eos/mm2]) was determined after examination of five microscopy
fields. For purposes of comparison to previous studies, eosinophil density was then
converted to eos/hpf for an assumed hpf size of 0.24 mm2, the size of an average field as
reported in the literature (7).
For immunohistochemistry (IHC), formalin-fixed paraffin-embedded tissue blocks were
masked to case and control status, sectioned (5 microns thick), and randomly sorted. Using a
high volume automated system (Dako Autostainer; Dako, Carpinteria, CA), IHC was
performed according to the following protocol. Slides were deparaffinized with xylene,
steam-treated for antigen retrieval (Target Retrieval Solution; Dako), incubated with the
primary antibodies of interest, incubated with a peroxidase-labelled anti-mouse polymer
secondary antibody (Envision; Dako), stained with a diaminobenzidine chromogen (DAB;
Innovex Biosciences, Richmond, CA), and then counterstained with hematoxylin. The
primary antibodies included: anti-MBP (mouse, clone BMK 13, 1:40 dilution, AbD Serotec,
Kidlington, UK and Raleigh, NC); anti-eotaxin-3 (mouse, #500-P156G, 1:50 dilution,
PeproTech, Rocky Hill, NJ), anti-LTA4H (rabbit, #160250, 1:300 dilution, Cayman
Chemical, Ann Arbor, MI); and anti-LTC4S (rabbit, #20108, 1:200 dilution, Santa Cruz
Biotechnology, Santa Cruz, CA). Lung, skin, and esophageal tissue were used as controls, as
per manufacturer recommendations. Positive control slides were incubated with primary
antibody while only antibody diluent (Dako, Carpinteria, CA) was added to the negative
control slides.
In a protocol that mirrored the one used for the eosinophil counts, the IHC glass slides were
scanned and converted to digital slides, and viewed with Aperio ImageScope (Aperio
Technologies, Vista, CA) (33). The maximum density of cells that stained positive for each
antibody of interest in the esophageal epithelial layer was quantified (cells/mm2) in five
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microscopy fields using the Aperio Positive Pixel Count Algorithm (version 9.1, Aperio
Technologies) (32).
Statistical analysis
Summary statistics were used to characterize the cases and controls. Bivariate analysis was
performed with Chi-square for categorical variables, and t-tests or Wilcoxon-Rank-sum tests
for continuous variables as appropriate. Correlations between eosinophil counts and
positively staining cells for each of the four antibodies were calculated by Pearson’s Rho
(R). Receiver operating characteristic (ROC) curves were constructed using EoE case status
as defined by the consensus diagnostic guidelines as the gold standard. The area under the
curve (AUC) was calculated and compared for seven different models predicting EoE case
status: MBP alone; eotaxin-3 alone; LTA4H alone; LTC4S alone; eosinophil count alone; a
combined model containing MBP and eotaxin-3; and a combined model containing MBP,
eotaxin-3, and the eosinophil count.
To assess possible confounding and misclassification of controls, we performed two pre-
planned sensitivity analyses. For the first, we limited the control group to only those with
erosive esophagitis noted on endoscopy in order to provide a comparison group with
documented pathologic acid exposure. For the second, we limited the control group to those
with ≥15 eos/hpf on esophageal biopsy. This focused the analysis on the GERD patients
with the highest levels of esophageal eosinophilia in whom the clinical diagnosis of EoE
would be most difficult. We also compared this GERD sub-population to the EoE cases with
fewer < 100 eos/hpf to further examine cases that might be clinically ambiguous. For these
comparisons, we repeated the bivariate and ROC analyses. In addition to these sensitivity
analyses we also repeated the main analyses after stratifying cases and control by age (adults
≥ 18 years vs children < 18 years), and for the subset of EoE cases without erosive
esophagitis on initial endoscopy.
All analyses were performed using Stata version 9 (Statacorp, College Station, TX). This
study was approved by the UNC Institutional Review Board.
Results
Patient characteristics
A total of 51 EoE cases and 54 GERD controls were included in this study (Table 1). EoE
cases were younger than GERD controls (24 vs 34 years; p = 0.01), had more dysphagia
(72% vs 31%; p < 0.001), and had more atopic diseases and food allergy. While the presence
of a hiatal hernia was more common in the GERD group, the other typical endoscopic
findings of EoE, including rings, furrows, and plaques, were more common in the EoE
group. The maximum eosinophil count was higher in the EoE group as compared to the
GERD group (143 vs 20 eos/hpf; p < 0.001), and EoE patients more commonly had
eosinophil degranulation, eosinophil microabscesses, and spongiosis (94%, 92%, and 92%,
respectively) compared with the GERD patients (43%, 11%, and 43%, respectively; p <
0.001 for all). As expected based on the control group definition, esophageal eosinophilia
was prominent in the GERD patients, mimicking the clinical situation in which is it
challenging to distinguish EoE and GERD.
MBP and eotaxin-3 staining in cases and controls
There was increased MBP and eotaxin-3 staining in EoE as compared to GERD (Figure 1A).
This impression was documented in the quantitative analysis (Table 2). The maximum MBP
staining density was significantly higher in the EoE group than in the GERD group (1479 vs
59 cells/mm2; p < 0.001), as was the maximum eotaxin-3 staining density (2219 vs 479
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cells/mm2; p < 0.001). A graphic representation of the MBP and eotaxin-3 staining
distributions (Figure 2A) demonstrates that the groups have substantially different
distributions, with relatively little overlap. These results were unchanged after the sensitivity
analysis limiting the GERD control group to only those with erosive reflux disease (n = 17;
maximum eosinophil count 25 ± 19 eos/hpf) or to only those with an esophageal eosinophil
count of ≥ 15 eos/hpf (n = 26; maximum eosinophil count 36 ± 23; data not shown). In the
overall study population, while MBP density and eosinophil count strongly correlated (R =
0.81; p < 0.001), correlation with eotaxin-3 was weaker (R = 0.25; p = 0.01). These results
also persisted after accounting for the different age distribution in the case and control
groups.
LTA4H and LTC4S staining in cases and controls
In contrast, there were few appreciable qualitative differences in LTA4H and LTC4S
staining between the EoE and GERD groups (Figure 1B). On quantitative analysis (Table 2),
there was no difference in LTA4H staining density in the EoE and GERD groups (575 vs
483 cells/mm2; p = 0.16), and LTC4S staining was somewhat lower in EoE as compared
with GERD (201 vs 388 cells/mm2; p = 0.001). When plotted, the case and controls had
substantial overlap in the staining distributions of both of these markers (Figure 2B). There
was poor to weak correlation between the eosinophil count and LTA4H (R = −0.02; p =
0.85) and LTC4S (R = −0.24; p = 0.02). These results were also unchanged after sensitivity
analysis (data not shown).
Tissue biomarkers for diagnosis of EoE
To investigate the utility of each of the four tissue biomarkers for diagnosis of EoE, ROC
curves were constructed (Figure 3). When MBP staining alone was used as the only
parameter in the model, it yielded an AUC of 0.96 for diagnosis of EoE as compared to
consensus guidelines as the gold standard. Using eotaxin-3 alone, the AUC was 0.87. The
AUCs for LTA4H and LTC4S were 0.58 and 0.66, respectively. For comparison, the AUC
for the eosinophil count alone was 0.89. The AUC for a combined model of MBP and
eotaxin-3 was 0.96. When MBP, eotaxin-3, and eosinophil count were combined in one
model, the AUC was 0.99. The AUC for MBP staining alone was significantly higher than
both those for eotaxin-3 alone (p = 0.006) and the eosinophil count alone (p = 0.03). The
combined MBP/eotaxin-3/eosinophil count AUC was significantly higher than the AUC for
the eosinophil count alone (p = 0.007), but not for MBP staining alone (p = 0.19; Figure 3).
On sensitivity analysis, the same results were noted after limiting the control group to only
those with erosive reflux disease or to only those with an esophageal eosinophil count of ≥
15 eos/hpf (data not shown). In addition, repeating this sensitivity analysis after excluding
cases of EoE with ≥ 100 eos/hpf who might be less likely to present a diagnostic challenge,
did not significantly changes the results (data not shown). Finally, the results were also
similar after stratifying patients by age (adult vs child) and after limiting the EoE cases to
those without erosive esophagitis (data not shown).
Discussion
Eosinophilic esophagitis is a clinicopathologic condition; the correct clinical and histologic
features are required to make the diagnosis, and the diagnostic guidelines emphasize the
importance of excluding competing causes of esophageal eosinophilia (1, 2). Because
clinical and histologic features of EoE and GERD overlap, in practical terms GERD is the
most common cause of esophageal eosinophilia that must be distinguished from EoE. (3–12)
This differentiation between EoE and GERD can be challenging but is crucial as
management strategies for the two conditions are divergent (1, 12).
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This study examined IHC staining of tissue biomarkers such as MBP, eotaxin-3, LTA4H,
and LTC4S for diagnosis of EoE by comparing EoE cases to GERD controls. These
biomarkers were selected specifically because they were felt to be pertinent to the
pathophysiology of EoE and unlikely to be increased in GERD (15, 20–22, 25, 27–31).
Moreover, the GERD controls were selected to have inflammation, including prominent
eosinophilia, on their esophageal biopsies in order to mimic the clinical situation in which it
can be difficult to distinguish EoE from GERD. We found that there was significantly higher
MBP and eotaxin-3 staining in the esophageal epithelium in EoE patients compared with
GERD patients, but that LTA4H and LTC4S staining was similar between the groups. This
result held even after limiting the controls to those with the highest eosinophil counts. In
addition, the correlation between the esophageal eosinophil count and MBP and eotaxin-3
staining was not high, suggesting that performing IHC could add diagnostic information to
the eosinophil count alone. On ROC analysis, the presence of increased numbers of cells
staining for MBP and eotaxin-3 was actually more predictive of EoE cases status than was
the eosinophil count itself. This is especially remarkable when one considers that the
eosinophil count is one of the components of the case definition of EoE. Moreover, the
combination of MBP staining, eotaxin-3 staining, and the eosinophil count nearly perfectly
distinguished EoE and GERD, but we acknowledge that by including the eosinophil count in
the ROC analysis, the predictive power of the model could be increased since eosinophil
count is also a component of the case definition.
These results are consistent with what is known about EoE pathogenesis. In an allergen-
induced Th2 response, factors such as IL-13 stimulate esophageal epithelial cells to produce
eotaxin-3, which in turn recruits eosinophils to the esophagus and leads to their activation
(15–17, 31). Eotaxin-3 cytokine levels (29, 31), tissue expression (27, 30), and blood levels
(28) are higher in EoE cases than in GERD controls or normal subjects. When eosinophils
are activated, they release intracellular granules, including MBP. MBP has been used to
immunolocalize eosinophils and characterize eosinophil degranulation on a qualitative basis
(20). Increased MBP staining and degranulation has been reported in EoE as compared to
GERD (21, 22). However, no prior study has explicitly examined the diagnostic utility of
MBP and eotaxin-3 in EoE with ROC analysis. Our results support the hypothesis that
performing IHC on esophageal biopsies for these biomarkers improves diagnostic accuracy.
In contrast, the role of leukotrienes in EoE is less well established. LTA4H and LTC4S are
key synthesis enzymes in the arachidonic acid pathway that metabolize precursors to
leukotriene effectors and are differentially expressed in EoE (27). There have been several
case series that report a clinical benefit of leukotriene antagonist therapy in patients with
EoE, (19, 34, 35) but there is debate as to whether this medication class is truly effective
(36). In addition, a prior study showed that cysteinyl leukotrienes levels were similar in EoE
patients and normal controls (18). Our results are consistent with these latter data, as
LTA4H and LTC4S staining were not helpful for differentiating EoE from GERD.
When interpreting the results from this study, there are several potential limitations to
consider. First, this was a retrospective study conducted at a single center with a highly
selected patient population. However, features of our EoE case population reflect the typical
characteristics of EoE populations reported from other centers and lend validity to the data
(37–42). Second, it is possible that there could have been misclassification of cases and
controls. However, because the EoE cases included in this study were extensively
characterized and met consensus EoE diagnostic criteria with exclusion of esophageal
eosinophilia (9, 14), misclassification of EoE patients is unlikely. Furthermore, had
misclassification occurred, the bias would have been towards the null with the reported
results representing an underestimation of the association between the biomarkers and the
disease state. Finally, the single time point of the analysis which was at diagnosis, limits
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conclusions that can be drawn about the diagnostic utility of these staining modalities in a
PPI-naïve patient population. Because this was a retrospective study that utilized samples
obtained prior to the recognition of PPI-responsive esophageal eosinophilia, we are unable
to comment on the utility of this staining approach in that population (1, 43, 44). The use of
MBP and eotaxin-3 staining will need to be validated prospectively in each of these patient
groups before it can be recommended for routine use, and efforts to do so are underway.
The strengths of this study include a large number of well characterized incident cases,
masked histologic re-review of esophageal biopsy specimens, and quantitative IHC analysis.
Because there is ongoing controversy concerning the relationships between EoE, GERD,
and esophageal eosinophilia (5, 45, 46), and because correct study group definitions are a
crucial feature of case-control studies, we also performed pre-planned sensitivity analyses.
That MBP and eotaxin-3 remained elevated in EoE, even when the EoE patients with lower
eosinophil counts were compared to GERD patients with high levels of esophageal
eosinophilia, implies that the activated eosinophils in EoE can be exploited to potentially
improve the diagnostic algorithm for EoE.
More generally, this study points to a novel diagnostic algorithm for EoE, which relies on
the pathogenic basis of the disease, as opposed to an arbitrary cutoff number of cells per
high powered field. In addition to being intuitively more appealing, such an approach has
other potential benefits. For instance, currently many patients diagnosed with EoE must
undergo two diagnostic upper endoscopies – an initial exam, often performed for dysphagia,
and a second, confirmatory exam after a course of acid suppressive therapy, to re-assess
eosinophil counts and to rule out PPI-responsive esophageal eosinophilia. An algorithm
assessing pathologic eosinophil activity has the potential to allow diagnosis at a single
endoscopy session. While the current work cannot substantiate this approach, future studies
should assess this highly clinically relevant question.
In conclusion, patients with EoE had substantially higher levels of MBP and eotaxin-3
staining in the esophageal epithelium compared with GERD patients, but there was no
difference between groups for LTA4H and LT4CS staining. Staining with MBP and
eotaxin-3 provided added diagnostic value beyond eosinophil counts alone, and MBP
staining in particular had the more prominent effect. Utilizing tissue biomarkers such as
MBP and eotaxin-3 may improve upon the current diagnostic standards by adding a measure
of eosinophil activity that is physiologically important, and could add a pathogenic basis to
the diagnosis of EoE.
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What is current knowledge?
• The clinical, endoscopic, and histologic features of eosinophilic esophagitis
(EoE) and gastroesophageal reflux disease (GERD) overlap substantially, and
differentiating the two can be challenging.
• Use of tissue biomarkers of eosinophil activation or inflammation may represent
a more efficient and pathophysiologically-based means for diagnosis of EoE.
• The diagnostic utility of factors such as major basic protein (MBP), eotaxin-3,
and leukotriene synthesis enzymes has not been established in EoE.
What is new here?
• Patients with EoE had substantially higher levels of MBP and eotaxin-3 staining
in the esophageal epithelium compared with GERD patients, but there was no
difference for leukotriene synthesis enzyme staining.
• The combination of MBP staining, eotaxin-3 staining, and the eosinophil count
nearly perfectly predicted EoE case status without taking into account other
clinical, endoscopic, or histologic features.
• Staining for MBP and eotaxin-3 may improve upon current EoE diagnostic
standards by adding a measure of eosinophil activity that is physiologically
important.
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Representative examples of immunohistochemistry staining. (A) H&E, MBP, and eotaxin-3
staining in a GERD and EoE patient. For H&E staining in GERD, there is basal layer
thickening, spongiosis, and an isolated eosinophil. In EoE, there is a brisk eosinophilia. For
IHC for both MBP and eotaxin-3, increased staining in EoE compared to GERD can be
appreciated (B) H&E, LTA4H, and LTC4S staining in a GERD and EoE patient. In this
instance, there are no qualitative differences in the IHC even though esophageal eosinophilia
is present in the EoE patient.
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Box and whiskers plots of staining density (mast cells/mm2) in the EoE and GERD groups
for (A) MBP and eotaxin-3, and (B) LTA4H and LTC4H. The median value for each group
is noted with the white line, the boxes represent the range of values from the 25th percentile
to the 75th percentile, the ends of the whiskers represent the 10th and 90th percentile of
values, and the dots are the maximum and minimum values.
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Receiver operating characteristic (ROC) curves for diagnosis of EoE using consensus
guidelines as the gold standard. The x-axis is 1-specificity and the y axis is sensitivity. The
dotted gray line represents a test that performs no better than chance, which by definition
has an area under the curve (AUC) of 0.5. A perfect test would have a curve with a line
parallel to the y-axis (specificity of 100%) and a line parallel to the x-axis (sensitivity of
100%), with an AUC of 1.0. In this figure, the AUC was calculated for seven conditions:
LTA4H staining alone; LTC4S staining alone; eotaxin-3 staining alone; MBP staining alone;
the eosinophil count alone; the combination of MBP and eotaxin-3; and the combination of
MBP, eotaxin-3, and the eosinophil count. Sensitivity and specificity are typically
maximized in the upper left-most area of each ROC curve. For example, for the MBP
staining alone ROC curve (dotted blue line), the maximum sensitivity and specificity are
90% and 91%, respectively, as noted with a black dot. For the ROC curve for the
combination of MBP and eotaxin three (dotted green line), the black dot represents the
maximum sensitivity and specificity of 90% and 94%, respectively. For the ROC curve for
the combination of MBP, eotaxin-3, and the eosinophil count (solid green line), the black
dot represents the maximum sensitivity and specificity of 95% and 94%, respectively. For
these latter two curves, aensitivity and specificity are maximized on the curves when the
MBP staining level is 300 cells/mm2 and the eotaxin-3 staining level is 600 cells/mm2.
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Mean age at biopsy (± SD) 24.2 ± 17.9 34.4 ± 22.0 0.01
Male subjects (n, %) 35 (69) 33 (61) 0.65
Caucasian subjects (n, %) 43 (84) 49 (91) 0.39
Symptoms (n, %)†
  Dysphagia 36 (72) 15 (31) < 0.001
  Food impaction 12 (27) 1 (2) 0.001
  Heartburn 16 (36) 28 (57) 0.04
  Abdominal pain 12 (27) 20 (43) 0.09
  Failure to thrive 8 (19) 6 (13) 0.50
Atopic disease (n, %)
  Allergic rhinitis/dermatitis 15 (34) 5 (11) 0.008
  Food allergy 5 (15) 1 (2) 0.034
  Asthma 11 (24) 3 (6) 0.02
Endoscopic characteristics
EGD findings (n, %)†
  Normal 7 (15) 16 (30) 0.07
  Rings 17 (35) 4 (7) < 0.001
  Linear furrows 12 (25) 0 < 0.001
  White plaques 7 (15) 0 0.004
  Erosive esophagitis 16 (33) 17 (31) 0.84
  Hiatal hernia 0 19 (35) < 0.001
Histologic characteristics
Max eosinophil density (eos/mm2)
  Mean (± SD) 597 ± 485 85 ± 93 < 0.001
Max eosinophil count‡
  Mean (± SD) 143 ± 116 20 ± 22 < 0.001
Histologic findings (n, %)
  Degranulation present 47 (94) 23 (43) < 0.001
  Microabscess present 36 (72) 6 (11) < 0.001
  Spongiosis present 46 (92) 23 (43) < 0.001
*
p value calculated with t-test for continuous variables and chi-square for categorical variables.
†
Patients could have more than one symptom or endoscopic characteristic.
‡
Determined from examination of 5 microscopy fields and calculated for a hpf area = 0.24 mm2.
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Table 2
Immunohistochemistry characteristics
EoE GERD p value*
Max major basic protein staining
  Mean cells/mm2 ± SD 1,479 ± 1,290 59 ± 103 < 0.001
  Median cells/mm2 (IQR) 1,076 (577–1959) 18 (4–58) < 0.001
Max eotaxin-3 staining
  Mean cells/mm2 ± SD 2,219 ± 1,782 479 ± 777 < 0.001
  Median cells/mm2 (IQR) 1,880 (709–3466) 295 (151–576) < 0.001
Max LTA4H staining
  Mean cells/mm2 ± SD 575 ± 351 483 ± 353 0.16
  Median cells/mm2 (IQR) 579 (255–805) 426 (223–645) 0.16
Max LTC4S staining
  Mean cells/mm2 ± SD 201 ± 187 388 ± 322 0.001
  Median cells/mm2 (IQR) 140 (77–278) 228 (116–584) 0.003
*
p value calculated with t-test for means and Wilcoxon rank sum for medians
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